Omar Noor, MD, FAAD

Noor, the co-owner of Rao Dermatology, shares about his interests in dermatology and what he most looks forward to as a member of our board.

Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.

Omar Noor, MD, FAAD, discusses the critical role of patient education and transparent communication in the context of treating individuals with atopic dermatitis. He emphasizes the significance of cultivating trust in patient-provider relationships, explores the potential necessity of shifting the treatment paradigm, and addresses the implications of treatment interruptions or transitions in the long-term management of this condition, all while considering the crucial aspect of access to care.

Omar Noor, MD, FAAD, discusses cultural competency in caring for patients with skin of color in dermatology.

Omar Noor, MD, FAAD, discusses his SDPA session, "Clinical Pearls for Pediatric and Adult Dermatology."

Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.

Three dermatologists discuss the case of an 18-year-old patient with AD who is exploring nonsteroidal options to manage his disease.

Drs Noor and Bhatia have a conversation about cost and financial assistance from pharmaceutical companies.

Drs Bhatia and Lamb discuss the case of a 12-year-old child with asthma and how they would manage his disease.

Experts discuss the case of a 4-year-old girl with lighter skin and treatment options for a young child.

Three experts emphasize the importance of setting expectations for AD treatment with patients.

Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Drs Noor and Lamb highlight the importance of frank discussion of adverse effects of atopic dermatitis treatments with patients.

Drs Bhatia, Lamb and Noor talk about the importance of building trust with patients and highlight topics to discuss with patients and parents.

Dermatology experts discuss strategies to increase awareness of advances in AD in patients with SOC.

Drs. Neal Bhatia and Angela Lamb provide an overview of atopic dermatitis and its prevalence in patients with skin of color (SOC).